Ovarian Cancer | Specialty

ESMO 2018: Dr. Cohen Reflects on Practice-Changing Data in Head and Neck Cancer

October 21st 2018

ESMO 2018: Dr. George Highlights Key Abstracts in Kidney and Prostate Cancers

October 21st 2018

ESMO 2018: Dr. Moore Speaks to Exciting PARP Inhibitor Abstracts in Ovarian Cancer

October 21st 2018

OncLive News Network On Location: In Munich Monday, October 22

October 21st 2018

OncLive News Network On Location: In Munich Sunday, October 21

October 21st 2018

OncLive News Network On Location: In Munich Saturday, October 20

October 21st 2018

Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer

October 21st 2018

The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have BRCA mutations, according to a posthoc analysis of the phase II QUADRA study.

Dr. Campos on Next Steps With PARP Inhibitors in Ovarian Cancer

October 15th 2018

Susana M. Campos, MD, gynecologic oncologist, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses next steps with PARP inhibitors in ovarian cancer.

Dr. Westin on PARP Resistance in Ovarian Cancer

October 9th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

New Law Widens Access to Genetic Counseling but Licensure and Coverage Barriers Persist

October 9th 2018

Telehealth, a universal term for the use of digital information and communication technologies to remotely access healthcare services, is improving availability of healthcare services, particularly for patients in rural areas.

Dr. Herzog on the Use of HIPEC in Ovarian Cancer

October 9th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

Dr. Powell on the Future of Immunotherapy in Ovarian Cancer

October 5th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses the future of immunotherapy in ovarian cancer.

Dr. Coleman on the Future of PARP Inhibitors in Ovarian Cancer

September 29th 2018

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of PARP inhibitors in patients with ovarian cancer.

Dr. Burgess on PARP Resistance in Ovarian Cancer

September 25th 2018

Brian T. Burgess, DO, first-year fellow, University of Kentucky Markey Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Dr. Konstantinopoulos Discusses PARP Plus Immunotherapy

September 22nd 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the combination of PARP inhibitors and immunotherapy.

Expert Emphasizes Education to Expand Genetic Testing

September 21st 2018

Jubilee Brown, MD, Brown explains the value of genetic testing for patients predisposed to and diagnosed with ovarian cancer.

Dr. Konecny on the Value of PARP Inhibitors in Ovarian Cancer

September 19th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Naumann on Improving Outcomes With Chemotherapy in Ovarian Cancer

September 19th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses improving outcomes with chemotherapy for the neoadjuvant treatment of patients with ovarian cancer.

Immunotherapy Could Still Have Pivotal Role in Ovarian Cancer

September 19th 2018

Matthew Powell, MD, discusses the promise of immunotherapy in ovarian cancer despite its challenges.

Coleman Covers Next Steps in Recurrent Ovarian Cancer

September 18th 2018

Robert L. Coleman, MD, FACOG, FACS, discusses the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.